Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells

Shigeyuki Suenaga, Yasuhiro Kuramitsu, Yufeng Wang, Byron Baron, Takao Kitagawa, Junko Akada, Kazuhiro Tokuda, Seiji Kaino, Shin Ichiro Maehara, Yoshihiko Maehara, Isao Sakaida, Kazuyuki Nakamura

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Gemcitabine (2′-deoxy-2′-difluorodeoxycytidine) is the only clinically effective drug for pancreatic cancer. However, high levels of inherent and acquired tumor resistance to gemcitabine lead to difficulty of chemotherapy for pancreatic cancer. We have reported on a proteomic study of gemcitabine-sensitive KLM1 and -resistant KLM1-R pancreatic cancer cells, and identified some proteins which were shown to be up-regulated in KLM1-R compared to KLM1 cells. In those proteomic studies, peroxiredoxin-2 was listed as an up-regulated protein in KLM1-R cells. Peroxiredoxin-2 is a member of a family of peroxiredoxins providing a protective role for redox damage. In this study, the expression of peroxiredoxin-2 in KLM1 and KLM1-R cells was compared. It was found that peroxiredoxin-2 was significantly up-regulated in KLM1-R cells compared to KLM1 cells (p<0.001). However, peroxiredoxin-1 expression was significantly down-regulated in KLM1-R cells (p<0.001). These results suggest that peroxiredoxin-2 is a possible candidate biomarker for predicting the response of patients with pancreatic cancer to treatment with gemcitabine.

Original languageEnglish
Pages (from-to)4821-4826
Number of pages6
JournalAnticancer research
Volume33
Issue number11
Publication statusPublished - Nov 1 2013

Fingerprint

gemcitabine
Peroxiredoxins
Pancreatic Neoplasms
Up-Regulation
Proteomics
Oxidation-Reduction
Proteins
Biomarkers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Suenaga, S., Kuramitsu, Y., Wang, Y., Baron, B., Kitagawa, T., Akada, J., ... Nakamura, K. (2013). Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. Anticancer research, 33(11), 4821-4826.

Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. / Suenaga, Shigeyuki; Kuramitsu, Yasuhiro; Wang, Yufeng; Baron, Byron; Kitagawa, Takao; Akada, Junko; Tokuda, Kazuhiro; Kaino, Seiji; Maehara, Shin Ichiro; Maehara, Yoshihiko; Sakaida, Isao; Nakamura, Kazuyuki.

In: Anticancer research, Vol. 33, No. 11, 01.11.2013, p. 4821-4826.

Research output: Contribution to journalArticle

Suenaga, S, Kuramitsu, Y, Wang, Y, Baron, B, Kitagawa, T, Akada, J, Tokuda, K, Kaino, S, Maehara, SI, Maehara, Y, Sakaida, I & Nakamura, K 2013, 'Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells', Anticancer research, vol. 33, no. 11, pp. 4821-4826.
Suenaga, Shigeyuki ; Kuramitsu, Yasuhiro ; Wang, Yufeng ; Baron, Byron ; Kitagawa, Takao ; Akada, Junko ; Tokuda, Kazuhiro ; Kaino, Seiji ; Maehara, Shin Ichiro ; Maehara, Yoshihiko ; Sakaida, Isao ; Nakamura, Kazuyuki. / Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. In: Anticancer research. 2013 ; Vol. 33, No. 11. pp. 4821-4826.
@article{4682a6e8d6174002bd442fbf27b269f4,
title = "Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells",
abstract = "Gemcitabine (2′-deoxy-2′-difluorodeoxycytidine) is the only clinically effective drug for pancreatic cancer. However, high levels of inherent and acquired tumor resistance to gemcitabine lead to difficulty of chemotherapy for pancreatic cancer. We have reported on a proteomic study of gemcitabine-sensitive KLM1 and -resistant KLM1-R pancreatic cancer cells, and identified some proteins which were shown to be up-regulated in KLM1-R compared to KLM1 cells. In those proteomic studies, peroxiredoxin-2 was listed as an up-regulated protein in KLM1-R cells. Peroxiredoxin-2 is a member of a family of peroxiredoxins providing a protective role for redox damage. In this study, the expression of peroxiredoxin-2 in KLM1 and KLM1-R cells was compared. It was found that peroxiredoxin-2 was significantly up-regulated in KLM1-R cells compared to KLM1 cells (p<0.001). However, peroxiredoxin-1 expression was significantly down-regulated in KLM1-R cells (p<0.001). These results suggest that peroxiredoxin-2 is a possible candidate biomarker for predicting the response of patients with pancreatic cancer to treatment with gemcitabine.",
author = "Shigeyuki Suenaga and Yasuhiro Kuramitsu and Yufeng Wang and Byron Baron and Takao Kitagawa and Junko Akada and Kazuhiro Tokuda and Seiji Kaino and Maehara, {Shin Ichiro} and Yoshihiko Maehara and Isao Sakaida and Kazuyuki Nakamura",
year = "2013",
month = "11",
day = "1",
language = "English",
volume = "33",
pages = "4821--4826",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells

AU - Suenaga, Shigeyuki

AU - Kuramitsu, Yasuhiro

AU - Wang, Yufeng

AU - Baron, Byron

AU - Kitagawa, Takao

AU - Akada, Junko

AU - Tokuda, Kazuhiro

AU - Kaino, Seiji

AU - Maehara, Shin Ichiro

AU - Maehara, Yoshihiko

AU - Sakaida, Isao

AU - Nakamura, Kazuyuki

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Gemcitabine (2′-deoxy-2′-difluorodeoxycytidine) is the only clinically effective drug for pancreatic cancer. However, high levels of inherent and acquired tumor resistance to gemcitabine lead to difficulty of chemotherapy for pancreatic cancer. We have reported on a proteomic study of gemcitabine-sensitive KLM1 and -resistant KLM1-R pancreatic cancer cells, and identified some proteins which were shown to be up-regulated in KLM1-R compared to KLM1 cells. In those proteomic studies, peroxiredoxin-2 was listed as an up-regulated protein in KLM1-R cells. Peroxiredoxin-2 is a member of a family of peroxiredoxins providing a protective role for redox damage. In this study, the expression of peroxiredoxin-2 in KLM1 and KLM1-R cells was compared. It was found that peroxiredoxin-2 was significantly up-regulated in KLM1-R cells compared to KLM1 cells (p<0.001). However, peroxiredoxin-1 expression was significantly down-regulated in KLM1-R cells (p<0.001). These results suggest that peroxiredoxin-2 is a possible candidate biomarker for predicting the response of patients with pancreatic cancer to treatment with gemcitabine.

AB - Gemcitabine (2′-deoxy-2′-difluorodeoxycytidine) is the only clinically effective drug for pancreatic cancer. However, high levels of inherent and acquired tumor resistance to gemcitabine lead to difficulty of chemotherapy for pancreatic cancer. We have reported on a proteomic study of gemcitabine-sensitive KLM1 and -resistant KLM1-R pancreatic cancer cells, and identified some proteins which were shown to be up-regulated in KLM1-R compared to KLM1 cells. In those proteomic studies, peroxiredoxin-2 was listed as an up-regulated protein in KLM1-R cells. Peroxiredoxin-2 is a member of a family of peroxiredoxins providing a protective role for redox damage. In this study, the expression of peroxiredoxin-2 in KLM1 and KLM1-R cells was compared. It was found that peroxiredoxin-2 was significantly up-regulated in KLM1-R cells compared to KLM1 cells (p<0.001). However, peroxiredoxin-1 expression was significantly down-regulated in KLM1-R cells (p<0.001). These results suggest that peroxiredoxin-2 is a possible candidate biomarker for predicting the response of patients with pancreatic cancer to treatment with gemcitabine.

UR - http://www.scopus.com/inward/record.url?scp=84891365055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891365055&partnerID=8YFLogxK

M3 - Article

C2 - 24222118

AN - SCOPUS:84891365055

VL - 33

SP - 4821

EP - 4826

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -